UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number: 001-42796
Nasus
Pharma Ltd.
P.O.
Box 284
Tel
Aviv, Israel 6100201
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
CONTENTS
Appointment
of Chief Financial Officer
On
November 11, 2026, Nasus Pharma Ltd. (the “Company”) appointed Mr. Nir Sassi as the Company’s Chief Financial Officer
(“CFO”). In connection with Mr. Sassi’s appointment as CFO, the Company entered into an Employment Agreement, dated
as of November 11, 2026, by and between the Company and Mr. Sassi.
In
connection with this appointment, the Company expects to enter into its standard form of indemnification agreement with Mr. Sassi on
the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive
officers. There are no related party transactions involving Mr. Sassi required to be disclosed under Item 7.B of Form 20-F.
Prior
to joining the Company Mr. Sassi served as Chief Financial Officer of Indaptus Therapeutics, Inc. (Nasdaq: INDP) from August 2021 to
April 2026. Before that, Mr. Sassi served as Chief Financial Officer of Intec Pharma Ltd. (formerly Nasdaq: NTEC) following his service
as a Senior Manager at PricewaterhouseCoopers Israel. Mr. Sassi holds a bachelor’s degree in economics and accounting from Ben-Gurion
University of the Negev, Israel, and is a certified public accountant in Israel.
Press
Release
On
November 16, 2026, the Company issued a press release titled “Nasus Pharma Appoints Nir Sassi as Chief Financial Officer,”
a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.
Incorporation
By Reference
This
Report of Foreign Private Issuer on Form 6-K (excluding the second, third and fifth paragraphs of the press release included as Exhibit
99.1 hereto) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-298693) and Form
S-8 (File Nos. 333-299524 and 333-296252), filed with the Securities and Exchange Commission, to be a part thereof from the date on which
this Report of Foreign Private Issuer is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT
INDEX
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release issued on November 16, 2026 by Nasus Pharma Ltd. titled “Nasus Pharma Appoints Nir Sassi as Chief Financial Officer” |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
NASUS PHARMA LTD. |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Brendan
O’Grady |
| |
Name: |
Brendan O’Grady |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1

Nasus
Pharma Appoints Nir Sassi as Chief Financial Officer
Seasoned
Biopharmaceutical Finance Executive Brings Nearly 25 Years of Experience in Capital Markets, Corporate Finance and Public Company Leadership
TEL
AVIV, Israel, November 16, 2026, (GLOBE NEWSWIRE) – Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or
the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today
announced the appointment of Mr. Nir Sassi as Chief Financial Officer, effective November 11, 2026. Mr. Sassi brings nearly 25 years
of experience in public company finance, capital markets, and biopharmaceutical operations to Nasus Pharma, and has served as chief financial
officer of two Nasdaq-listed biopharmaceutical companies.
“We
are delighted to welcome Nir to Nasus Pharma,” said Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma. “Nir
brings a wealth of financial leadership experience, a strong track record in the capital markets, and a deep understanding of the biopharmaceutical
industry. His expertise and perspective will be particularly valuable as Nasus enters an important phase of its development, and I am
confident he will be a strong addition to our leadership team.”
“Nir
joins us at an important time as we prepare to initiate our planned NS002 pivotal study and finalize our pre-commercial plans,”
said Brendan O’Grady, Chief Executive Officer of Nasus Pharma. “His record of financial and operational management for biopharmaceutical
companies will provide us with important support as we progress NS002 toward a pivotal clinical Phase 3 study in the fourth quarter of
2026 and a topline data readout in the first quarter of 2027. I look forward to working with Nir as we advance NS002 and our Nasax®
platform programs toward their full clinical and commercial potential.”
Mr.
Sassi most recently served as Chief Financial Officer of Indaptus Therapeutics, Inc., a Nasdaq-listed clinical-stage biopharmaceutical
company, where he oversaw its financial operations, strategic financial planning, and capital markets activities. Previously, he served
as Chief Financial Officer of Intec Pharma Ltd. and began his professional career at PwC. Mr. Sassi holds a B.A. in Economics and Accounting
from Ben-Gurion University of the Negev and is a Certified Public Accountant in Israel.
“I
am excited to join Nasus Pharma at this stage of the Company’s development,” said Mr. Sassi. “NS002 has the potential
to offer patients and caregivers an intranasal alternative to injectable epinephrine for severe allergic reactions, and the Nasax®
platform supports a growing pipeline of intranasal product candidates across multiple therapeutic areas. I look forward to working with
Brendan, Udi, and the entire Nasus Pharma team to support disciplined execution and to build long-term value for our shareholders.”
The
Company plans to initiate its pivotal clinical Phase 3 study in the fourth quarter of 2026 and have a topline data readout from that
study in the first quarter of 2027.
Additional
information regarding Mr. Sassi’s appointment will be furnished by the Company in a Report of Foreign Private Issuer on Form 6-K
with the U.S. Securities and Exchange Commission (the “SEC”).
About
Nasus Pharma Ltd.
Nasus
Pharma Ltd. (NYSE American: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal
powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment
for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to
develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug
delivery across multiple therapeutic areas. For further information about the Company, please visit www.nasuspharma.com or follow on
Twitter (X) or LinkedIn.
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release
are forward-looking statements, including statements regarding: the Company’s expectations regarding its growth, the advancement
of its clinical programs, and anticipated clinical and commercial milestones; the planned timing of the planned NS002 pivotal clinical
Phase 3 study and topline data readout the Company’s plans to strengthen its financial and operational capabilities and build its
leadership team; that Mr. Sassi’s experience will prove highly valuable to the Company; the significant opportunity of the Company’s
intranasal drug delivery platform and its ability to bring innovative drug delivery products to patients and address significant unmet
medical needs; and the Company’s beliefs about the impact of its leadership additions, including the appointment of Mr. Sassi,
on its long-term growth and execution of its corporate strategy. Forward-looking statements contained in this press release may be identified
by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “target,” “aim,” “should,” “will” “would,”
or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult
to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.
These risks include, among others, risks relating to regulatory interactions and alignment, the timing and outcome of the planned NS002
pivotal clinical Phase 3 study, topline data readout, clinical-trial results, regulatory approval, the Company’s ability to obtain
additional financing, and the development and implementation of pre-commercial and commercial plans. These and other risks and uncertainties
are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with
the SEC on March 25, 2026 and in the Company’s subsequent filings and reports furnished to the SEC. Forward-looking statements
contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required
under applicable law.
Corporate
Contact
Nasus
Pharma Ltd. Israel
info@nasuspharma.com
Investors
Contact
Mike
Moyer
LifeSci
Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com